Evidence map›Paper›PMID 34297139›Full record

ReviewDer Radiologe2021

[Primary treatment of prostate cancer using 1.5 T MR-linear accelerator].

Daniel Wegener, Daniel Zips, Cihan Gani, Simon Boeke, Konstantin Nikolaou, Ahmed E Othman, Haidara Almansour, Frank Paulsen, Arndt-Christian Müller

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Der Radiologe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Daniel WegenerUniversitätsklinik für Radioonkologie, Universitätsklinikum Tübingen, Eberhard Karls Universität Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland. Daniel.Wegener@med.uni-tuebingen.de.
Daniel ZipsUniversitätsklinik für Radioonkologie, Universitätsklinikum Tübingen, Eberhard Karls Universität Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland.
Cihan GaniUniversitätsklinik für Radioonkologie, Universitätsklinikum Tübingen, Eberhard Karls Universität Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland.
Simon BoekeUniversitätsklinik für Radioonkologie, Universitätsklinikum Tübingen, Eberhard Karls Universität Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland.
Konstantin NikolaouUniversitätsklinik für Radiologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
Ahmed E OthmanUniversitätsklinik für Radiologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
Haidara AlmansourUniversitätsklinik für Radiologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
Frank PaulsenUniversitätsklinik für Radioonkologie, Universitätsklinikum Tübingen, Eberhard Karls Universität Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland.
Arndt-Christian MüllerKlinik für Radioonkologie und Strahlentherapie, Ludwigsburg, Deutschland.
University of Tübingen · DEKlinik und Poliklinik für Strahlentherapie und Radioonkologie · DEUniversitätsklinikum Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHybrid devices of MR-scanners and linear accelerators (MR-Linacs) represent a new and promising extension of radiotherapeutic options for prostate cancer. The potential advantage of magnetic resonance imaging (MRI) over computed tomography (CT) for soft tissue contrast is well-known and leads to more consistent and smaller target volumes and improved normal tissue sparing.

objectivesThis article presents an overview of clinical experience, indications, advantages and challenges of utilizing a 1.5 T MR-Linac in the setting of radiotherapy of prostate cancer.

resultsAll current indications for radiotherapy of prostate cancer can be treated with an MR-Linac. The advantages include daily MR-based imaging in treatment position and daily adaption of the treatment plan on current anatomy (adaptive radiotherapy). Additionally, functional MRI sequences might be exploited to enhance treatment individualization and response assessment. Ultimately treatment on an MR-Linac might further increase the therapeutic window. The limitations of using MR-Linac include treatment complexity and the duration of each session.

conclusionsMR-Linacs expand the spectrum of radiotherapeutic options for prostate cancer. Increased precision can be reached with daily MRI-based target volume definition and plan adaption. Clinical studies are necessary to identify patient groups who would benefit most from radiotherapy on a MR-Linac.

Indexed as

Prostatic NeoplasmsRadiotherapy, Image-GuidedHumansMagnetic Resonance ImagingMaleParticle AcceleratorsRadiotherapy Planning, Computer-AssistedAdaptive radiotherapyMR-guided radiotherapyPatient positioningRadiosurgerySoft tissue contrast

Identifiers

PMID34297139
PMCPMC8410708
OpenAlexW3185811779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.